Bachmann-Bupp syndrome and treatment.
Level 5 - mechanism / opinion, no new human data
Narrative review of disease mechanisms and repurposed drug therapy without systematic review or new controlled data
PubMed 37469105 · doi:10.1111/dmcn.15687
What was done
This is a narrative review describing the clinical presentation, molecular pathophysiology, and therapeutic approach for Bachmann-Bupp syndrome (BABS), a neurodevelopmental disorder caused by mutations in the ornithine decarboxylase 1 (ODC1) gene.
What was found
The abstract reports no numerical data. Mechanistically, C-terminal truncation of ODC prevents ubiquitin-independent proteasomal degradation, causing catalytic accumulation of ODC and dysregulated polyamine synthesis. Repurposing the ODC inhibitor α-difluoromethylornithine (DFMO, eflornithine) has been reported to improve hair growth, muscle tone, and developmental progress in patients with BABS.
Why it matters
It outlines a precision drug repurposing pathway for an ultra-rare genetic disorder, using an existing safe pediatric agent (DFMO) to counteract enzymatic gain-of-function.
Limits
No quantitative data, sample size, or systematic outcome measures are reported in the abstract. Evidence is limited to narrative review and mechanistic case reports for an ultra-rare disease without controlled trial data.